Findings

What do systematic reviews say?

7 questions · 7 findings · 3 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 3 · 42.9%High 1 · 14.3%

Overall survival (1‐year · people with pancreatic and periampullary adenocarcinoma

It is very uncertain whether extended changes overall survival (1‐year compared with standard lymph node resection (very low certainty).

1 finding from 1 review

Overall survival (3‐year · people with pancreatic and periampullary adenocarcinoma

It is very uncertain whether extended changes overall survival (3‐year compared with standard lymph node resection (very low certainty).

1 finding from 1 review

Overall survival

Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic radiotherapy (moderate certainty).

1 finding from 1 review

Extended‐field radiotherapy for locally advanced cervical cancer 2018 · Cochrane Headline outcomes only
HR 0.67 [0.48, 0.94]
1 study · 337 participants
Moderate

Overall survival

Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic chemoradiotherapy (moderate certainty).

1 finding from 1 review

Extended‐field radiotherapy for locally advanced cervical cancer 2018 · Cochrane Headline outcomes only
HR 0.5 [0.39, 0.64]
1 study · 389 participants
Moderate

Overall survival

It is very uncertain whether extended‐field chemoradiotherapy changes overall survival compared with pelvic chemoradiotherapy (very low certainty).

1 finding from 1 review

Extended‐field radiotherapy for locally advanced cervical cancer 2018 · Cochrane Headline outcomes only
HR 0.37 [0.14, 0.96]
1 study · 74 participants
Very low

Overall survival · people with metastatic colorectal cancer ‐ extended RAS WT

The intervention leads to lower overall survival (high certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.77 [0.67, 0.88]
4 studies · 1053 participants
High

Overall survival · people with metastatic colorectal cancer ‐ extended RAS MT

The intervention showed no clear difference in overall survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.09 [0.93, 1.28]
4 studies · 1768 participants
Moderate